Date: 2014-07-21
Type of information: Grant
Company: Celsion (USA - NJ)
Investors: National Institutes of Health\'s Center for Biomedical Imaging and Bioengineering (NIBIB) (USA)
Amount: $1 million
Funding type: grant
Planned used: The grant will support preclinical studies evaluating ThermoDox®, Celsion\'s heat-activated liposomal encapsulation of doxorubicin, in combination with High Intensity Focused Ultrasound (HIFU), for the treatment of brain tumors. The grant, titled \"Controlled Delivery and Release of Chemotherapy in Brain Tumors with FUS\" provides on average of $200,000 in annual funding for five years, and will be used to advance preclinical development of ThermoDox® for the treatment of brain cancers, including GBM, under the Company\'s January 2014 collaboration with Brigham and Women\'s Hospital, Harvard Medical School. If promising results are obtained from these Phase I studies, a Phase II grant application will be submitted to include more comprehensive studies of ThermoDox® and HIFU for the treatment of GBM brain tumors.
Others: * On July 21, 2014, Celsion, a leading oncology drug development company, announced that its ongoing collaboration with Dr. Costas Arvanitis of Brigham and Women\'s Hospital, a teaching affiliate of Harvard Medical School, has been expanded through the recent award of a $1 million Career Development Award from the National Institutes of Health\'s Center for Biomedical Imaging and Bioengineering (NIBIB). The grant will support preclinical studies evaluating ThermoDox®, the Company\'s heat-activated liposomal encapsulation of doxorubicin, in combination with High Intensity Focused Ultrasound (HIFU), for the treatment of brain tumors. This drug is also being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer.
Therapeutic area: Cancer - Oncology
